FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225282307> ?p ?o ?g. }

• W4225282307 endingPage "555" @default.
• W4225282307 startingPage "554" @default.
• W4225282307 abstract "A decade has passed since the first prospective trials showed that the mammography technology, digital breast tomosynthesis, increased the rate of cancer detection compared with digital mammography. 1 Ciatto S Houssami N Bernardi D et al. Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison study. Lancet Oncol. 2013; 14: 583-589 Summary Full Text Full Text PDF PubMed Scopus (608) Google Scholar , 2 Skaane P Bandos AI Gullien R et al. Prospective trial comparing full-field digital mammography (FFDM) versus combined FFDM and tomosynthesis in a population-based screening programme using independent double reading with arbitration. Eur Radiol. 2013; 23: 2061-2071 Crossref PubMed Scopus (170) Google Scholar A large body of evidence, comprising prospective non-randomised studies and retrospective studies, 3 Marinovich ML Hunter KE Macaskill P Houssami N Breast cancer screening using tomosynthesis or mammography: a meta-analysis of cancer detection and recall. J Natl Cancer Inst. 2018; 110: 942-949 Crossref PubMed Scopus (108) Google Scholar has since accumulated; however, evidence from randomised controlled trials is scarce. In The Lancet Oncology, Walter Heindel and colleagues report the results of the TOmosynthesis plus SYnthesised MAmmography Study (TOSYMA), 4 Heindel W Weigel W Gerß J et al. Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, superiority trial. Lancet Oncol. 2022; (published online April 12.)https://doi.org/10.1016/S1470-2045(22)00194-2 Summary Full Text Full Text PDF PubMed Scopus (1) Google Scholar a multicentre trial embedded in the German population-wide mammography screening programme. TOSYMA is the largest of three randomised controlled trials providing evidence on breast tomosynthesis versus mammography screening. 4 Heindel W Weigel W Gerß J et al. Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, superiority trial. Lancet Oncol. 2022; (published online April 12.)https://doi.org/10.1016/S1470-2045(22)00194-2 Summary Full Text Full Text PDF PubMed Scopus (1) Google Scholar , 5 Hofvind S Holen AS Aase HS et al. Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trial. Lancet Oncol. 2019; 20: 795-805 Summary Full Text Full Text PDF PubMed Scopus (38) Google Scholar , 6 Pattacini P Nitrosi A Giorgi RP et al. A randomized trial comparing breast cancer incidence and interval cancers after tomosynthesis plus mammography versus mammography alone. Radiology. 2022; (published online Feb 1.)https://doi.org/10.1148/radiol.211132 Crossref PubMed Scopus (3) Google Scholar Heindel and colleagues persevered with TOSYMA despite the COVID-19 pandemic stalling recruitment, resulting in a marginally lower sample size than planned in their adaptive design. 4 Heindel W Weigel W Gerß J et al. Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, superiority trial. Lancet Oncol. 2022; (published online April 12.)https://doi.org/10.1016/S1470-2045(22)00194-2 Summary Full Text Full Text PDF PubMed Scopus (1) Google Scholar Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, superiority trialThe results from this study indicate that the detection rate for invasive breast cancer was significantly higher with digital breast tomosynthesis plus s2D mammography than digital mammography alone. Evaluation of interval cancer rates in the follow-up study will further help to investigate incremental long-term benefits of digital breast tomosynthesis screening. Full-Text PDF" @default.
• W4225282307 created "2022-05-04" @default.
• W4225282307 creator A5003268089 @default.
• W4225282307 date "2022-05-01" @default.
• W4225282307 modified "2023-10-16" @default.
• W4225282307 title "Should tomosynthesis replace mammography for breast cancer screening?" @default.
• W4225282307 cites W2009232173 @default.
• W4225282307 cites W2113622720 @default.
• W4225282307 cites W2123869011 @default.
• W4225282307 cites W2885655595 @default.
• W4225282307 cites W2944758817 @default.
• W4225282307 cites W3137437064 @default.
• W4225282307 cites W3141560986 @default.
• W4225282307 cites W4210285958 @default.
• W4225282307 cites W4210535138 @default.
• W4225282307 cites W4225388971 @default.
• W4225282307 doi "https://doi.org/10.1016/s1470-2045(22)00215-7" @default.
• W4225282307 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35427472" @default.
• W4225282307 hasPublicationYear "2022" @default.
• W4225282307 type Work @default.
• W4225282307 citedByCount "1" @default.
• W4225282307 countsByYear W42252823072023 @default.
• W4225282307 crossrefType "journal-article" @default.
• W4225282307 hasAuthorship W4225282307A5003268089 @default.
• W4225282307 hasConcept C121608353 @default.
• W4225282307 hasConcept C126322002 @default.
• W4225282307 hasConcept C143998085 @default.
• W4225282307 hasConcept C147454874 @default.
• W4225282307 hasConcept C19527891 @default.
• W4225282307 hasConcept C2780472235 @default.
• W4225282307 hasConcept C2781281974 @default.
• W4225282307 hasConcept C2908647359 @default.
• W4225282307 hasConcept C2909182381 @default.
• W4225282307 hasConcept C530470458 @default.
• W4225282307 hasConcept C71924100 @default.
• W4225282307 hasConcept C99454951 @default.
• W4225282307 hasConceptScore W4225282307C121608353 @default.
• W4225282307 hasConceptScore W4225282307C126322002 @default.
• W4225282307 hasConceptScore W4225282307C143998085 @default.
• W4225282307 hasConceptScore W4225282307C147454874 @default.
• W4225282307 hasConceptScore W4225282307C19527891 @default.
• W4225282307 hasConceptScore W4225282307C2780472235 @default.
• W4225282307 hasConceptScore W4225282307C2781281974 @default.
• W4225282307 hasConceptScore W4225282307C2908647359 @default.
• W4225282307 hasConceptScore W4225282307C2909182381 @default.
• W4225282307 hasConceptScore W4225282307C530470458 @default.
• W4225282307 hasConceptScore W4225282307C71924100 @default.
• W4225282307 hasConceptScore W4225282307C99454951 @default.
• W4225282307 hasIssue "5" @default.
• W4225282307 hasLocation W42252823071 @default.
• W4225282307 hasLocation W42252823072 @default.
• W4225282307 hasOpenAccess W4225282307 @default.
• W4225282307 hasPrimaryLocation W42252823071 @default.
• W4225282307 hasRelatedWork W2000845075 @default.
• W4225282307 hasRelatedWork W2035416953 @default.
• W4225282307 hasRelatedWork W2054671076 @default.
• W4225282307 hasRelatedWork W2334042002 @default.
• W4225282307 hasRelatedWork W2439033010 @default.
• W4225282307 hasRelatedWork W2538424924 @default.
• W4225282307 hasRelatedWork W2905305767 @default.
• W4225282307 hasRelatedWork W3086198586 @default.
• W4225282307 hasRelatedWork W3210538750 @default.
• W4225282307 hasRelatedWork W4294145423 @default.
• W4225282307 hasVolume "23" @default.
• W4225282307 isParatext "false" @default.
• W4225282307 isRetracted "false" @default.
• W4225282307 workType "article" @default.